- Home
- PCYO vs INBX Comparison
PCYO vs INBX Comparison
Compare PCYO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- INBX
- Stock Information
- Founded
- PCYO 1976
- INBX 2010
- Country
- PCYO United States
- INBX United States
- Employees
- PCYO N/A
- INBX N/A
- Industry
- PCYO Water Supply
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- INBX Health Care
- Exchange
- PCYO Nasdaq
- INBX Nasdaq
- Market Cap
- PCYO 267.7M
- INBX 345.8M
- IPO Year
- PCYO N/A
- INBX 2020
- Fundamental
- Price
- PCYO $11.43
- INBX $26.54
- Analyst Decision
- PCYO
- INBX Hold
- Analyst Count
- PCYO 0
- INBX 2
- Target Price
- PCYO N/A
- INBX N/A
- AVG Volume (30 Days)
- PCYO 36.4K
- INBX 112.9K
- Earning Date
- PCYO 11-12-2025
- INBX 11-13-2025
- Dividend Yield
- PCYO N/A
- INBX N/A
- EPS Growth
- PCYO 123.89
- INBX N/A
- EPS
- PCYO 0.56
- INBX N/A
- Revenue
- PCYO $27,447,000.00
- INBX $1,400,000.00
- Revenue This Year
- PCYO N/A
- INBX N/A
- Revenue Next Year
- PCYO N/A
- INBX N/A
- P/E Ratio
- PCYO $19.99
- INBX N/A
- Revenue Growth
- PCYO 40.36
- INBX N/A
- 52 Week Low
- PCYO $9.65
- INBX $10.81
- 52 Week High
- PCYO $14.63
- INBX $30.23
- Technical
- Relative Strength Index (RSI)
- PCYO 68.49
- INBX 52.65
- Support Level
- PCYO $10.80
- INBX $27.51
- Resistance Level
- PCYO $11.50
- INBX $28.86
- Average True Range (ATR)
- PCYO 0.32
- INBX 1.38
- MACD
- PCYO 0.08
- INBX -0.37
- Stochastic Oscillator
- PCYO 87.18
- INBX 8.54
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.